Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.

Abstract

Docetaxel administered at 100 mg/m2 intravenously every 3 weeks has notable activity against platinum-refractory non-small-cell lung cancer, with a 21% major response rate. Primary side effects were neutropenia, hypersensitivity, and fluid retention.